InMed Pharmaceuticals Inc. · NASDAQ:INM

InMed Pharmaceuticals — Merger or Acquisition (September 2021)

16 slides from InMed Pharmaceuticals's merger presentation, September 2021

  1. Slide 1: InMed Pharmaceuticals Acquiring BayMedica

    InMed Pharmaceuticals Acquiring BayMedica Establish market leadership in the manufacturing and development of rare cannabinoids September 2021 :INM www.inmedpharma.com

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: unlocking the full potential of cannabinoid p

  3. Slide 3: Create shareholder value by combining complementary business models

    Create shareholder value by combining complementary business models A Cannabinoid Pharmaceutical Company Manufacturer and Supplier to the Consumer Health & Wellness Market • Pharmaceutical-grade, proprietary approach for synthesized • Proprietary manufacturing platforms for naturally occurring rare

  4. Slide 4: Why This Acquisition is Transformational

    Why This Acquisition is Transformational Create a pure-play cannabinoid (CB) company with unparalleled, multi-faceted manufacturing capacity and strong clinical expertise Create Market Leader in Leader in a variety of cannabinoid manufacturing approaches Manufacturing Increase Commercial Substantial

  5. Slide 5: Unparalleled Cannabinoid Manufacturing Expertise

    Unparalleled Cannabinoid Manufacturing Expertise Chemical IntegraSyn™ Synthesis Biosynthesis • Utilizes very high efficiency, biosynthesis • Preferred for CBs with simple structure and • Preferred for complex structures at very derived enzyme CB analog R&D large scale • Flexibility to shift from pro

  6. Slide 6: Combined Manufacturing Expertise to Support Target End Markets

    Combined Manufacturing Expertise to Support Target End Markets Production of rare cannabinoids used for pharmaceutical and consumer health and wellness Pharmaceutical Cannabinoid Consumer Health Manufacturing & Wellness Expertise Pharmaceutical-grade Multiple cannabinoid manufacturing Immediate and

  7. Slide 7: Extensive Combined Assets, Capabilities, and Commercial Potential

    Extensive Combined Assets, Capabilities, and Commercial Potential Leading Manufacturing Know-How Large Market Presence • Sector-leading position in several CB • Speed & access to commercial markets / revenues manufacturing methods; able to select most • Existing B2B sales in the US health/wellness m

  8. Slide 8: Extensive Patent Protection for Combined Company

    Extensive Patent Protection for Combined Company Major opportunity for expansion of patent portfolio of new chemical entities • A growing library of new analogs targeting diverse diseases • Patent applications covering the biosynthetic pathway and semi-synthetic production of both natural cannabinoi

  9. Slide 9: BayMedica Manufacturing Expertise in Rare CBs for Consumer Health & Wellness

    BayMedica Manufacturing Expertise in Rare CBs for Consumer Health & Wellness Advancing multiple rare cannabinoids to commercialization 100+ Rare Cannabinoids Stage of Requires synthetic manufacturing Development < 1% for commercial viability Major Cannabinoids 2-20% CBC Commercial Easy to extract fr

  10. Slide 10: Cannabinoid Synthesis Demand Expected to Drive Exponential Market Growth

    Cannabinoid Synthesis Demand Expected to Drive Exponential Market Growth 120 $115B 100 80 Global cannabinoid synthesis market $60B estimated to grow 60 from $10B in 2025 to $115B by 2040 40 $30B 20 $10B $200M 0 Source: Raymond James, Sept 2020 2020 2025 2030 2035 2040 10

  11. Slide 11: Growing Revenue from Current Commercial Product – Cannabichromene (CBC)

    Growing Revenue from Current Commercial Product – Cannabichromene (CBC) Multiple Wholesale Markets in Features of BayMedica ProDiol® CBC Consumer Health and Wellness ● Global leader in CBC large batch supply Prodiol® CBC ● Non-intoxicating; not scheduled by DEA ls Sup tica ple ceu ● Consumer health

  12. Slide 12: Bringing Together a Depth of Cannabinoid Expertise

    Bringing Together a Depth of Cannabinoid Expertise Eric A. Adams, MIBS Shane Johnson, MD Chief Executive Officer SVP and General Manager BayMedica 30+ years of experience in global biopharma leadership 20+ years strategic planning/ execution with LEK Consulting in BusDev, S&M with enGene, QLT, Abbot

  13. Slide 13: Financial Snapshot

    Financial Snapshot INM Cash and Short-term Investments (Mar 31, 2021)* $9.5 M1 Shares I/O 12.1 M2 Options (Mar 31, 2021) 0.9 M Warrants 6.5 M Fully Diluted Shares, September 10, 2021 19.5M4 Previous Close (2021-09-10) US$2.11 52-week High3 US$8.94 52-week Low3 US$2.02 Avg. Daily Volume (Trailing 50

  14. Slide 14: Combined Short-term Milestones to Drive Shareholder Value

    Combined Short-term Milestones to Drive Shareholder Value Manufacturing • Continue to drive revenues from current ProDiol® CBC product • Launch several new cannabinoids into B2B Consumer Packaged Goods space • Integrate manufacturing teams and technical know-how to prioritize next projects Drug Deve

  15. Slide 15: Long-term Growth Strategy

    Long-term Growth Strategy Advancing a global leader in the manufacturing and development of rare cannabinoids Accelerate Launch new cannabinoids into the consumer & health and Revenue Growth wellness space Advance Drug Deliver clinically proven CBN-based drugs for unmet medical Development needs in

  16. Slide 16: Thank you!

    UNLOCKING THE POTENTIAL OF CANNABINOID MEDICINES Thank you! Colin Clancy Senior Director, Investor Relations cclancy@inmedpharma.com +1-604-416-0999 :INM www.inmedpharma.com

InMed Pharmaceuticals — Merger or Acquisition (September 2021) on 6ix